CAM
ITCI

ClariVest Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

ClariVest Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$559K Hold
8,164
– – 0.06% 343
2024
Q2 		$559K Buy
8,164
+3,194
+64% +$222K 0.06% 343
2024
Q1 		$344K Buy
+4,970
New +$342K 0.04% 369
2022
Q3 		– Sell
-7,633
Closed -$436K – 768
2022
Q2 		$436K Hold
7,633
– – 0.02% 393
2022
Q1 		$467K Buy
+7,633
New +$396K 0.02% 397

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClariVest Asset Management's ITCI Position: Q3 2024 in Review

ClariVest Asset Management held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q3 2024 at 8,164 shares worth $559K. The position accounts for 0.06% of the portfolio, ranked #343.

ClariVest Asset Management first reported a position in ITCI in Q1 2022 and has held it in 5 quarters since. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • ClariVest Asset Management held 8,164 shares of Intra-Cellular Therapies Inc. worth $559K as of Q3 2024.
  • ClariVest Asset Management left its Intra-Cellular Therapies Inc. share count unchanged in Q3 2024.
  • Intra-Cellular Therapies Inc. made up 0.06% of ClariVest Asset Management's portfolio in Q3 2024, its #343 holding.
  • ClariVest Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and has held it in 5 quarters since.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.